Polyglutamine (polyQ) disorders

The chromatin connection

Donit Cohen-Carmon and Eran Meshorer*

Department of Genetics; The Institute of Life Sciences; The Hebrew University of Jerusalem; Edmond J. Safra Campus; Jerusalem, Israel

Keywords: chromatin, disease, polyglutamine (polyQ), neurodegeneration, HDAC inhibitors, pluripotent stem cells, iPSCs

Polyglutamine (polyQ)-related diseases are dominant late-onset genetic disorders that are manifested by progressive neurodegeneration, leading to behavioral and physical impairments. An increased body of evidence suggests that chromatin structure and epigenetic regulation are involved in disease pathology. PolyQ diseases often display an aberrant transcriptional regulation due to the disrupted function of histone-modifying complexes and altered interactions of the polyQ extended proteins with chromatin-related factors. In this review we describe recent findings relating to the role of chromatin in polyQ diseases. We discuss the involvement of epigenetic-related factors and chromatin structure in genomic instability of CAG repeats; we describe changes in the expression and regulation of chromatin-related enzymes and in the levels and patterns of histone modifications in disease state; we illustrate the potential beneficial effects of different histone deacetylase (HDAC) inhibitors for the treatment of polyQ diseases, and we end by describing the potential use of human pluripotent stem cells and their differentiated derivatives for modeling polyQ diseases in vitro. Taken together, these accumulating studies strongly suggest that disrupted chromatin regulation may be directly involved with the pathophysiology of polyQ-related diseases.

Introduction

Polyglutamine-expansion disease family encompasses at least nine heritable disorders, including Huntington’s disease (HD) and the spinocerebellar ataxias SCA1, SCA2, SCA3, SCA6, SCA7 and SCA17 (reviewed in ref. 1). Each of these disorders results from the expansion of a CAG repeat, coding for a glutamine tract (polyQ) that is present in the wild-type protein. While in healthy individuals the polyQ tract varies between 35–50 repeats, depending on the disease, in patients or carriers, the polyQ tract reaches above 40 and often over 100 glutamines. These repeat expansion mutations are unstable, resulting in changes in repeat length between generations as well as between different cells and tissues of the same person. Curiously, polyQ-containing proteins are ubiquitously expressed throughout the body, while the pathology is primarily restricted to neuronal tissue. The mechanisms that are responsible for this specificity are largely unknown.

Recent studies provided strong evidence for the involvement of chromatin in the etiology of polyQ neurodegenerative pathogenesis. Chromatin, the eukaryotic scaffold for gene regulation, is primarily regulated by chemical modifications of histones, which are the basic structural proteins around which the genomic DNA is wrapped (see Box 1 for details). Histone modifications play essential roles in the regulation of chromatin structure by preventing or facilitating transcription. Notably, accumulating data suggest a potential therapeutic role for drugs that target chromatin, such as histone deacetylase (HDAC) inhibitors, in a number of polyQ models.

In this review we discuss different aspects of epigenetic-related mechanisms involved in the etiology of polyQ-related diseases: epigenetics of genomic instability; the histone milieu of the expanded repeat tract, changes in histone modifications and histone-modifying complexes, potential use of drugs that target chromatin, and finally, human pluripotent stem cell models as promising tools to study polyQ diseases in vitro.

Instability and Chromatin Structure in polyQ Diseases

Genomic instability is triggered by the tendency of trinucleotide repeats to form alternative structures, such as hairpins and slipped-strand duplexes. These abnormal structures, which lead to changes in repeat length, can occur during DNA replication, repair, recombination and transcription.\(^4\) CAG repeat expansions occur during multiple stages of human development, both in the germline and in the soma. Long CAG repeats, resulting in long polyQ tracts disrupt neuronal function and exacerbate disease pathology. The dynamics of instability often differs in the male and female germline, and typically varies from tissue to tissue. In HD for example, large expansions occur mostly through paternal transmissions. The repeat length will usually determine the age of onset and disease severity, a correlation known as “anticipation.”\(^5\)

What are the mechanisms that affect repeat instability? Multiple studies in recent years suggest the involvement of bidirectional transcription (simultaneous sense and antisense transcription, a.k.a., convergent transcription), RNA interference (RNAi) machinery, and chromatin structure. Bidirectional transcription, through a long CAG tract, produces double stranded...
Repeat instability is also affected by histone acetylation.

Histone Modifications in polyQ Diseases

As indicated above, chromatin structure is greatly influenced by histone modifications. Histones can be methylated, acetylated, phosphorylated, ubiquitinated and sumoylated on multiple residues through the action of specialized enzymes. Several modifications, such as H3 acetylation on lysine 9 (H3K9ac) or H3K4me3, are correlated with active chromatin, while other modifications, e.g., H3K9me3 or H4K20me3 are associated with inactive chromatin. The interplay between the different histone modifier complexes determines chromatin structure and function (Box 1).

Huntington disease. HD is a late-onset autosomal dominant neurodegenerative disorder, characterized by involuntary movements, progressive cognitive decline and emotional liability. The disorder is caused by an expanded CAG repeat (>36) in the first exon of the HTT gene. Despite the expression of the mutant HTT protein in essentially all brain regions, there is a specific progressive loss of cortical and striatal neurons. Although neuronal death mechanisms are not entirely understood, transcriptional dysregulation and aberrant chromatin remodeling are central features in HD pathology, and may provide some explanations. In support, the WT HTT protein interacts with a number of transcription factors and histone modifiers, including CBP, SP1, TFII, p50, Sin3a, and REST/NRSF.

Most of what we know about HD in general, and particularly about the involvement of chromatin modifiers, comes from studies in animal models. Animal models, especially mouse and fly, recapitulate to a large extent, the behavioral, biochemical and neuropathological phenotypes that are characteristic of HD. Two of the most widely characterized HD transgenic mouse models are the R6/2 and N171-82Q (82Q) models, which express different lengths of the Fmr1 N-terminus gene, containing 150 and 171 CAG repeats respectively. As noted above, CBP plays an important role in HD. The stronger interaction of CBP with the mutant HTT leads to CBP depletion and to hypoacetylation of histones H3 and H4 in brains of R6/2 mice. This hypoacetylation is considered to occur late in HD pathology. Moreover, monovalent deletion of CBP triggers the induction of the H3K9 histone methyltransferase ESET and an increase in H3K9me3, leading to condensation of pericentromeric heterochromatin in neurons. CBP depletion was also shown to be associated with cognitive dysfunction and long-term memory deficiency in HD. In agreement, in a Drosophila model of HD, which contains the first 548 amino acids of the human HTT gene with a pathogenic 128 polyQ repeat tract, upregulation of CBP expression rescued HD phenotypes. However, partial depletion of CBP in HD that promoted expansion. HDAC3 inhibition, using either small molecules or siRNAs, was able to partially relieve the expansion-associated gene silencing in vitro in both yeast and human cells, and to suppress somatic expansions that contribute to disease progression.

Taken together, these studies demonstrate the involvement of epigenetic regulation, both locally and globally, in repeat instability vis-à-vis disease pathology and progression.

Box 1. Chromatin structure and function. The genome in eukaryotic cells is packaged in the form of chromatin. Chromatin consists primarily of DNA and histone proteins. The fundamental unit of chromatin is the nucleosome, which is comprised of 146 bp of DNA wrapped around an histone octamer made up of 2 copies each of the core histones, H2A, H2B, H3 and H4. PROTOSomely from the nucleosome are the histone N-terminal tails, which can be modified on multiple residues. The control of eukaryotic gene expression largely depends on histone tail modifications. These include (but not limited to) acetylation, methylation, phosphorylation, ubiquitination and sumoylation, all of which play important roles in the regulation of gene expression by influencing chromatin structure and by recruiting regulatory proteins and enzymes. Some modifications, such as histone acetylation, are strongly associated with gene activation, while others (e.g., H3 lysine 9 methylation) are associated with heterochromatin and gene suppression.

Histone acetylation is further demonstrated by knocking out one allele of the DNA methyltransferase Dnmt1 in a SCA1 (see below) mouse model. Partial Dnmt1 deficiency caused a significant increase in the DNA methyltransferase Dnmt1 in a SCA1 (see below) mouse model. Partial Dnmt1 deficiency caused a significant increase in DNA hypermethylation and aberrant DNA methylation around the CTCF binding site at CpG loci, implying a role for epigenetic regulation in repeat instability. The involvement of DNA methylation in polyQ-related repeat instability was further demonstrated by knocking out one allele of the DNA methyltransferase Dnmt1 in a SCA1 (see below) mouse model. Partial Dnmt1 deficiency caused a significant increase in intergenerational expansions in the germline, without affecting somatic tissues. In addition, these mice displayed aberrant DNA methylation and elevated H3 lysine 9 (H3K9) methylation at sites within the CpG island around the expanded repeat tract, demonstrating a connection between local chromatin environment and repeat instability.

Repeat instability is also affected by histone acetylation.

Histone modifications in polyQ diseases involve a complex interplay between bidirectional transcription, RNAi, and chromatin structure influences repeat instability. Repeat instability is also affected by cis-regulatory elements and trans-acting factors. One example is the binding of CTCF to its target sequence (CCCTC). In SCA7 (see below) transgenic mice with CTCF binding-site mutations, CTCF binding is impaired, leading to increased somatic repeat instability. Instability was associated with DNA hypermethylation around the CTCF binding site at CpG loci, implying a role for epigenetic regulation in repeat instability.

Telomeric repeats in SCA1 and HD fly models. Treatment with the HDAC inhibitor (HDACi) trichostatin A (TSA) suppressed repeat instability in SCA3 (see below) and HD fly models. Treatment with the HDAC inhibitor (HDACi) trichostatin A (TSA) suppressed repeat instability by resumption of acetylation levels. Along the same lines, a screen for proteins involved in repeat expansion instability identified several HDACs, including HDAC3
Spinocerebellar ataxia type 1 (SCA1) is a dominantly neurodegenerative disease resulting from polyQ expansion (> 39) in the ataxin-1 (ATXN1) gene. ATXN1 interacts directly with Tip60, the catalytic subunit of a HAT complex, which is involved in transcriptional activation by acetylating H4 and H2A. Partial loss of Tip60, obtained by crossing SCA1-82Q transgenic mice with Tip60+/- mice, delayed ATXN1-mediated cerebellar degeneration during mid-stage disease progression. These results suggest that Tip60 plays a transient role during SCA1 disease progression, although the exact mechanisms are not entirely understood.

Machado-Joseph disease (MJD; SCA3) is a dominantly inherited late-onset neurodegenerative disorder caused by polyQ expansion in the deubiquitinating enzyme ATXN3. Expanded polyQ fragments promote the generation of ATXN3-containing aggregates in brains of MJD patients and MJD mouse models. The formation of early aggregation intermediates is thought to have a critical role in disease initiation, but the precise pathogenic mechanism operating in MJD has remained largely elusive. Interestingly, ATXN3, both wild-type and mutant, was shown to interact with the histone acetyltransferases CBP, p300 and PCAF, and to inhibit transcriptional activation by these proteins, linking it directly with chromatin regulation. It should also be noted that ATXN3 binds HDAC6, but since HDAC6 is a cytoplasmic HDAC which acts mostly on tubulin and does not bind histones in vivo, the relation to chromatin is indirect, and is perhaps confined to its inhibition by HDACi.

SCA7, caused by ATXN7 expansion, is characterized by cone-rod retinal degeneration, progressive neuronal dysfunction and cerebellar cell death. ATXN7 protein, both normal and polyQ-expanded, is a component of the mammalian SAGA and SLIK HAT complexes. PolyQ-expanded ATXN7 transgenic mice did not contribute to HD pathogenesis, showing no clear impact on striatal degeneration, motor impairment, mutant HTT aggregation, or global levels of acetylated histones H3 or H4 in the brain. Therefore, further studies are required to delineate the role of CBP in HD and decipher whether the different models used in these studies account for the seemingly contrasting results.

Aberrant histone modifications in HD are not restricted to acetylation and methylation. Monoubiquitination of histone H2A (uH2A), which is associated with gene repression, was also shown to be implicated. Mutant HTT has been shown to mediate H2A monoubiquitination through a disrupted interaction with Brm1, a component of the hPRC1/E3 ubiquitin ligase complex. This disrupted interaction leads to increased uH2A levels in a cell culture model system of HD and in R6/2 mice. Promoters of repressed genes in these mice show increased uH2A levels, while expressed genes display the opposite trend. However, crossing the R6/2 mice with mice heterozygous for the polyubiquitin gene (Ubc), prevented uH2A accumulation, and no transcriptional and neurological improvements were recorded. These data suggest a complex involvement of the ubiquitin system in the pathology of HD, which warrants further investigation.

Finally, an important factor that was implicated in the transcriptional dysregulation in HD is REST, which represses neuronal genes in non-neuronal tissues including undifferentiated neuronal progenitors, by binding to a DNA sequence element known as RE1. Intriguingly, in HD neurons, REST translocates from the cytoplasm to the nucleus, where it recruits several chromatin-modifying enzymes, induces the repression of key target genes such as BDNF. Taken together, these data demonstrate the important role that histone modifying enzymes and histone modifications play in different stages of HD.

Figure 1. Chromatin involvement in repeat instability. Some chromatin-related mechanisms that lead to repeat instability are depicted. Bidirectional transcription of long CAG repeats generates double stranded RNA, which is processed by the RNAi machinery into short RNAs that form hairpins. These short CAG RNAs promote heterochromatin production, resulting in transcription inhibition. Double stranded RNA of CAG repeats can also induce apoptosis, leading to polyQ-related pathology. Perturbed CTCF binding and low Dmt1 expression levels were also reported to promote instability.

Ataxias. Spinocerebellar ataxia type 1 (SCA1) is a dominant neurodegenerative disease resulting from polyQ expansion (> 39) in the ataxin-1 (ATXN1) gene. ATXN1 interacts directly with Tip60, the catalytic subunit of a HAT complex, which is involved in transcriptional activation by acetylating H4 and H2A. Partial loss of Tip60, obtained by crossing SCA1-82Q transgenic mice with Tip60+/- mice, delayed ATXN1-mediated cerebellar degeneration during mid-stage disease progression. These results suggest that Tip60 plays a transient role during SCA1 disease progression, although the exact mechanisms are not entirely understood.

Machado-Joseph disease (MJD; SCA3) is a dominantly inherited late-onset neurodegenerative disorder caused by polyQ expansion in the deubiquitinating enzyme ATXN3. Expanded polyQ fragments promote the generation of ATXN3-containing aggregates in brains of MJD patients and MJD mouse models. The formation of early aggregation intermediates is thought to have a critical role in disease initiation, but the precise pathogenic mechanism operating in MJD has remained largely elusive. Interestingly, ATXN3, both wild-type and mutant, was shown to interact with the histone acetyltransferases CBP, p300 and PCAF, and to inhibit transcriptional activation by these proteins, linking it directly with chromatin regulation. It should also be noted that ATXN3 binds HDAC6, but since HDAC6 is a cytoplasmic HDAC which acts mostly on tubulin and does not bind histones in vivo, the relation to chromatin is indirect, and is perhaps confined to its inhibition by HDACi.

SCA7, caused by ATXN7 expansion, is characterized by cone-rod retinal degeneration, progressive neuronal dysfunction and cerebellar cell death. ATXN7 protein, both normal and polyQ-expanded, is a component of the mammalian SAGA and SLIK HAT complexes. PolyQ-expanded ATXN7 transgenic mice did not contribute to HD pathogenesis, showing no clear impact on striatal degeneration, motor impairment, mutant HTT aggregation, or global levels of acetylated histones H3 or H4 in the brain. Therefore, further studies are required to delineate the role of CBP in HD and decipher whether the different models used in these studies account for the seemingly contrasting results.

Aberrant histone modifications in HD are not restricted to acetylation and methylation. Monoubiquitination of histone H2A (uH2A), which is associated with gene repression, was also shown to be implicated. Mutant HTT has been shown to mediate H2A monoubiquitination through a disrupted interaction with Brm1, a component of the hPRC1/E3 ubiquitin ligase complex. This disrupted interaction leads to increased uH2A levels in a cell culture model system of HD and in R6/2 mice. Promoters of repressed genes in these mice show increased uH2A levels, while expressed genes display the opposite trend. However, crossing the R6/2 mice with mice heterozygous for the polyubiquitin gene (Ubc), prevented uH2A accumulation, and no transcriptional and neurological improvements were recorded. These data suggest a complex involvement of the ubiquitin system in the pathology of HD, which warrants further investigation.

Finally, an important factor that was implicated in the transcriptional dysregulation in HD is REST, which represses neuronal genes in non-neuronal tissues including undifferentiated neuronal progenitors, by binding to a DNA sequence element known as RE1. Intriguingly, in HD neurons, REST translocates from the cytoplasm to the nucleus, where it recruits several chromatin-modifying enzymes, inducing the repression of key target genes such as BDNF. Taken together, these data demonstrate the important role that histone modifying enzymes and histone modifications play in different stages of HD.
The mutated ATXN7 to the pathology of SCA7, involving bidirectional transcription, altered chromatin regulation, distorted SAGA activity and dysregulated transcription of target genes in the nervous system. It also warrants investigation of potential similar mechanisms in other polyQ diseases, such as HD, in which a CTCF binding site in the HTT gene was identified, leading to disease phenotypes. In addition, in a transgenic mouse model expressing polyQ-expanded ATXN7 in rod photoreceptors, the rod cells nuclei showed chromatin decondensation due to altered distribution of the linker histone H1c. The loss of SAGA function by polyQ-ATXN7 can affect the time of onset and severity of SCA7 phenotypes. As noted above, the ATXN7 gene contains binding sites for CTCF. In addition to its effect on repeat instability as discussed earlier, CTCF binding promotes transcription of antisense non-coding RNA from an alternative promoter and mediates high levels of the repressive histone mark H3K27me3. Mice harboring mutations in the CTCF-recognition region of polyQ-ATXN7 demonstrated that the loss of antisense transcription induced ATXN7 sense transcription accompanied by reduced H3K27me3 and increased H3K9/H3K14 acetylation levels, leading to disease formation. These data show the multifaceted contribution of the mutated ATXN7 to the pathology of SCA7, involving bidirectional transcription, altered chromatin regulation, distorted SAGA activity and dysregulated transcription of target genes in the nervous system. It also warrants investigation of potential similar mechanisms in other polyQ diseases, such as HD, in which a CTCF binding site in the HTT gene was identified, leading to disease phenotypes. In addition, in a transgenic mouse model expressing polyQ-expanded ATXN7 in rod photoreceptors, the rod cells nuclei showed chromatin decondensation due to altered distribution of the linker histone H1c. The loss of SAGA function by polyQ-ATXN7 can affect the time of onset and severity of SCA7 phenotypes.

Table 1. Beneficial effects of HDAC inhibition or suppression in polyQ disease models

| HDACi/treatment | PolyQ model | Effect | Refs. |
|-----------------|-------------|--------|-------|
| SAHA            | HD R6/2 mice | Improvement of motor skills | 57, 58 |
| SAHA            | Human HTT in yeast | Inhibition of neurotoxic metabolites | 59 |
| NuBu            | SCA3 mice | Restoration of histone acetylation level | 60 |
| 4b              | HD R6/2 mice | Improvement of neurological symptoms | 61 |
| 4b-related compounds | HD R6/2 mice | Improvement of motor, body-weight and brain symptoms | 62 |
| Sir2 / Rpd3 reduction | HD flies | Neuroprotection | 63 |
| Sir11 increase | HD mice | Improvement of motor skills and decreased neurodegeneration | 64 |

Figure 2. Chromatin involvement in spinocerebellar ataxia type 7 (SCA7). CTCF binding at the promoter region of the ATXN7 gene promotes H3K27 methylation and antisense transcription from an alternative promoter. Impaired binding of CTCF abolishes H3K27 methylation and suppresses antisense transcription, along with induced polyQ-ATXN7 sense transcription, leading to disease phenotypes. In addition, the ATXN7 protein (blue) is a component of both the SAGA and the SLIK HAT complexes. PolyQ-ATXN7 protein disrupts HAT activity of these complexes, resulting in chromatin disruption, retinal degeneration and SCA7 disease.
non-coding transcription, and suggest the involvement of altered chromatin conformation in the regulation of ATXN8 expression. This example joins the growing list of cases, a few of which are depicted above, in which chromatin structure and epigenetic mechanisms are involved in the regulation of poly-Q expanded protein function. It was therefore natural to consider chromatin-directed compounds as potential drugs for poly-Q-related diseases.

HDAC Inhibitors as Potential Therapy for polyQ Diseases

HDAC enzymes are divided into four different classes: class I (HDAC1, 2, 3 and 8), class IIa (HDAC4, 5, 7 and 9), class IIb (HDAC6 and 10), class III (SIRT1-7) and class IV (HDAC11). Class I, II and IV are zinc-dependent, while the class III Sirtuins use NAD+ as a cofactor for their catalytic activity.53 Classes I, II and IV are zinc-dependent, while the class III Sirtuins use NAD+ as a cofactor for their catalytic activity.53 HDAC inhibitors (HDACi) block HDAC activity, resulting in increased histone acetylation, although much like the HDACs themselves, the selectivity of the HDACs are relatively poor and most available HDACi target a mixture of different HDACs. Of these, several have been examined for their potential beneficial effects in polyQ disease models (Table 1). Below we provide some notable examples.

Suberoylanilide hydroxamic acid (SAHA) is a potent HDAC inhibitor which targets class I HDACs, as well as the class II HDAC6, and which crosses the blood-brain-barrier (BBB).54-56 In the R6/2 HD mouse model, SAHA was shown to increase histone acetylation in the brain, and improve motor impairments.57 Interestingly, SAHA chronic administration into the drinking water of R6/2 HD mice leads to HDAC2 and HDAC4 protein degradation, although their transcript levels remain unaltered. Moreover, in the same mouse model, Htr aggregation in the cortex and brain stem is reduced, along with normalization of Bdnf cortical transcript levels.58 In another study, SAHA inhibited the HDAC3-dependent generation of neurotoxic metabolites by mutant Htr in both yeast and in microglia of R6/2 mice.59 In light of these findings, SAHA seems to be a promising agent for the treatment of poly-Q diseases, although because of its poor selectivity, it is not clear which of the different HDACs is responsible for the effects.

The HDACi Sodium Butyrate (NaBu), which inhibits HDAC1, 2, 4, 5 and 7, and akin to SAHA, which crosses the BBB, was shown to have beneficial effects in an HD and SCA3 mouse models. In SCA3 transgenic mice, NaBu was shown to reverse poly-Q-ATXN5-mediated histone hypoacetylation and to improve neurological symptoms and survival of the mice.60 In R6/2 HD mice, NaBu treatment increased life-expectancy and improved motor and neural symptoms.61 NaBu increased acetylation of histones and of the Sp1 transcription factor and restored the otherwise reduced expression of α and β globins as well as MKP1 in R6/2 mice.62 This suggests that HDACγ-mediated increased acetylation may relieve poly-Q-mediated suppression of target genes. However, global changes in the levels of histone acetylation affect many other genes, likely causing additional, less beneficial effects.

Supporting this notion, several studies demonstrate the complexity of the relationship between histone modifications and gene expression changes. The HDAC inhibitor 4b shows therapeutic effects of motor, body-weight, brain and striatal degeneration in HD R6/2 transgenic mice. As expected, 4b reversed histone H3 hypoacetylation in association with restoration of expression levels of many transcripts, although interestingly, it also decreased the expression of specific genes associated with cell death, cell cycle, and the immune response.63 Moreover, the non-toxic selective HDACi 4b-related compounds were found lately to specifically inhibit HDMC3 and HDMC4 effectively. This specific targeting led to an improvement of neurodegenerative effects in various cell culture, fly and mouse HD models.64 In a Drosophila HD model, in which an N-terminal fragment of the human mutant (93Q) HTT is expressed in all neurons, Sir2 and Rpd3 (the mammalian HDAC3 ortholog) were found, among all the HDACs, to contribute to HD pathology. Reducing their levels individually in heterogeneous flies, exerted neuroprotection effects, and their combined reduction augmented this observed protective effect further.65 In contrast, in a mouse model of HD, mutant Htt binds Sirt1 (the mammalian Sir2 ortholog), inhibits its deacetylase activity, and leads to hyperacetylation of Sirt1 targets. Thus, increased Sirt1 level ameliorates motor impairment and neurodegeneration in mouse, and reduction of Sirt1 exacerbates mutant Htt toxicity.66 This discrepancy is likely due to the different HD model systems used, and calls for investigating Sirt1 function in human models.

In addition to HDAC inhibitors, which have limited specificity and may have pleiotropic effects, the effects of targeting specific HDACs were also examined. Reducing the levels of HDAC3 or HDAC7 in R6/2 mice by crossing them with HDAC3-/- and HDAC7-/- heterozygous mice respectively, did not ameliorate HD neurodegenerative symptoms, although both HDAC3 and HDAC7 were shown to be affected by SAHA administration in the brains of R6/2 mice.66,67 Full knockout of HDAC6 in R6/2 mice also had no beneficial effects.68 Thus, while SAHA and other HDACi may be promising agents in the treatment of poly-Q diseases, their direct targets are usually still largely unknown, although as mentioned above, HDAC2 and HDAC4 are prime suspects in the case of HDAC inhibition by SAHA.69 Taken together, these data demonstrate that although targeting HDACs in poly-Q diseases is a promising avenue (Table 1), the lack of selective agents and the limited effect of targeting a specific HDAC diminish the overall initial enthusiasm.

To circumvent these issues, it may be necessary to examine a combinatorial approach of specific HDAC-targeting, or to develop more selective HDACi in order to fine-tune neuroprotection and improve neurodegenerative symptoms. In addition, the recently emerging human pluripotent model systems (see below) for studying neurodegenerative diseases are an important novel resource for studying disease mechanisms and ultimately for screening potential HDACi and other optional drugs.
Studies of chromatin structure, repeat instability, RNA toxicity, polyQ function, neurodegeneration and disease phenotype improvement by chromatin-modifying enzymes have so far been performed, by and large, on other organisms than humans. The experimental models for neurodegenerative diseases based on other-than-human organisms such as flies and transgenic mice have many limitations in relation to disease mode characteristics, and often the results obtained in one model may not be recapitulated in another, let alone in humans. However, human tissue is a scarce reagent. Biopsies of human brain tissue are not easily obtained, and often the results obtained in one model may not be recapitulated in another, let alone in humans. However, human tissue is a scarce reagent. Biopsies of human brain tissue are not easily accessible, and when available, neurons do not divide in vitro. Therefore, pluripotent disease-bearing human cell lines offer great promise over existing models (Table 2).

Pluripotent stem cells (PSCs) are defined by their ability to self-renew indefinitely in culture and to generate any cell type in vitro or in vivo. Human PSCs (hPSCs) can be derived from somatic cells using Oct4, Sox2 and Klf4 (with or without c-Myc) gene expression, and is active, and is silenced by promoter methylation and suppressive histone modifications upon differentiation. In contrast, FMR1 gene is heterochromatinized and silenced, FMR1 is not activated, and promoter methylation persists. These results suggest that while human pluripotent models offer unprecedented opportunities, each system must be carefully scrutinized to ensure that it properly recapitulates the relevant disease.

Table 2. Phenotypes of polyQ-iPSC models

| iPSC model          | Phenotype                                                                 |
|---------------------|---------------------------------------------------------------------------|
| HD Rhesus monkey model | Aggregation of mutant HTT, formation of intranuclear inclusions in differentiated neurons  |
| HD R6/2 mice (heterozygous and homozygous) | Increased lysosomal activity, altered cholesterol metabolic pathway  |
| HD hiPSC            | Increased lysosomal activity, altered cholesterol metabolic pathway  |
| HD hiPSC            | Progressive vacuolization upon astrocyte differentiation in vitro and in vivo  |
| HD hiPSC            | Behavioral improvements of HD symptoms upon neuronal precursors transplantation into HD rat brain  |
| MJD hiPSC           | Excitation-dependent accumulation of ATXN3 aggregates; calcium-induced proteolysis of ATXN3  |

| Human Pluripotent Models for polyQ-Related Diseases |

In addition, in order to study disease mechanisms in pluripotent cell models, they first must be differentiated into the relevant mature, post-mitotic, functional neuronal subtypes. Based on knowledge of embryogenesis and developmental studies, we can now use combinations of morphogens and neurotrophins to induce specific lineage committed cells, including neurons, from PSCs. In HD, for example, loss of cortical and striatal neurons is the main pathological feature as disease progresses. Differentiation of pluripotent cells into striatal neurons has already been achieved, and their function was examined upon transplantation into rat or mouse brains. The field of in vitro differentiation is continuously growing, and protocols for selective neuronal induction are constantly being established.

iPSCs from a Rhesus monkey model of HD have recently been generated, characterized and differentiated into neurons. These monkey HD-iPSCs displayed characteristic features of HD, including the accumulation of mutant Htt aggregates and the formation of intranuclear inclusions upon neural differentiation in vitro, suggesting that iPSC-derived neurons can be used successfully to model polyQ diseases.

More recently, several iPSC lines from HD patients and R6/2 transgenic mice were generated. Although CAG repeat expansion had no effect on reprogramming efficiency, proliferation rate, BDNF level, or neurogenic potential, the R6/2 derived iPSCs as well as their neuronal differentiated progeny showed increased lysosomal activity and altered cholesterol biosynthetic pathway, which are hallmarks of HD. In another study, human HD-iPSCs were differentiated into striatal neurons in a step-wise manner. The differentiating neurons showed enhanced caspase activity upon growth factor deprivation compared with normal differentiating cells. In both these studies, the repeat length was shown to be stable and similar to that of the patients, and was not affected by the reprogramming or the differentiation process. In another recent study, HD-iPSCs displayed normal neuronal differentiation both in vitro and in vivo upon mouse brain transplantation, but interestingly, when differentiated into astrocytes, they showed progressive vacuolization, characteristic of HD astrocytes. Finally, transplantation of neuronal precursors generated from HD-iPSCs into the brain of an HD rat model, improved behavioral impairments associated with HD.

MJD has also been recently successfully modeled using iPSCs. Neurons generated from iPSCs of MJD patients revealed excitation-dependent accumulation of the ATXN3 aggregates.

In summary, iPSC technology is providing a powerful tool to model polyQ diseases.
Glutamate-mediated neuronal induction caused calcium-induced proteolysis of ATXN3, leading to the formation of ATXN3 insoluble aggregates.82 Taken together, these studies strongly support the idea that iPSCs can successsfully model polyQ disorders (Table 2) despite the late onset phenotypes observed in humans.66,67 The enthusiasm for the use of pluripotent cell models to model and study diseases in vitro, caution should be practiced. Patient cell biopsies may differ significantly between one another; the passage of the cells may greatly influence the reprogramming process and the end result; additionally, since the iPSC derivation process itself is cumbersome, many variations among different lines may occur, including chromosomal aberrations,77,78 and it is therefore essential to compare several different lines; also, as is the case with the Fragile X example discussed above, HEKs and iPSCs may display major differences in chromatin structure and disease-related phenotypes; the passage of the pluripotent cells themselves may also create significant variation between experiments and lead to epigenetic instability; and finally, the lengthy neuronal differentiation process can also be a major cause for experimental variation and heterogeneity. Careful measures are therefore essential to ensure the creation of proper, reproducible pluripotent models.

Recently, several studies have demonstrated the ability to directly convert human fibroblasts into functional neurons without the need for pluripotent intermediates. In these studies, an expression of a combination of a small set (usually around 5) of defined factors or microRNAs were sufficient to convert fibroblasts to neurons at an efficiency that greatly exceeds that of reprogramming fibroblasts to pluripotency.88-92 Since the pluripotent state is the Achilles heel of cell therapy, holding the terrifying potential to proliferate in vivo, the direct conversion approach (beyond the scope of this review) provides a promising alternative approach for regenerative medicine, and will no doubt attract significant attention in the years to come. The use of human PSCs for regenerative medicine still faces some significant challenges in the clinical field, including safety, efficacy, and the exact differentiation stage suitable for transplantation.93 Regardless, human PSCs are already providing a unique and unmatched source for basic science. They are also gradually gaining momentum for the use of high-throughput drug screens, and for testing specific compounds, as demonstrated in several studies which focused on neuronal disorders.94-96 With the current pace, we anticipate that such reprogrammed or converted cells will become standard procedure for the treatment of neurodegenerative diseases in general and for polyQ disorders in particular.

Acknowledgments
We thank Dr Malca Nissim-Rafinia (Jerusalem) for comments; the Safran Foundation, the ISF Legacy-Heritage Brain Medical Program (943/09 and 125/12), the Israel Ministry of Science, the Israel Ministry of Health (6007), the Israel Cancer Research Foundation and the European Research Council (ERC-287781) for financial support. E.M. is the Joseph H. and Belle R. Braun Senior Lecturer in Life Sciences. D.C.C. is an Eshkol Fellow of the Israel Ministry of Science.

References
1. Ott HT, Zeggari HV. Trinucleotide repeat diseases. Annu Rev Genet 2007; 41:279-302; PMID:17447957; http://dx.doi.org/10.1146/annurev.genet.41.110406.110842.
2. Liu Y, Wilson HH. DNA base excision repair: a mechanism of trinucleotide repeat expansion. Trends Biochem Sci 2010; 35:43-9; PMID:20293556; http://dx.doi.org/10.1016/j.tibs.2009.12.002.
3. Duan Y, Wilson HH. Instability and chromatin structure of expanded trinucleotide repeats. Trends Genet 2009; 25:288-97; PMID:19540013; http://dx.doi.org/10.1016/j.tig.2009.04.007.
4. Goodall M, Elgin SC. Transcription and RNA interference in the formation of heterochromatin. Nature 2007; 447:399-406; PMID:17522071; http://dx.doi.org/10.1038/nature05794.
5. Morris KV, Chen JW, Jacobson JS, Lessey DE. Small interfering RNA-induced transcriptional gene silencing in human cells. Science 2004; 305:1289-90; PMID:15035262; http://dx.doi.org/10.1126/science.1101672.
6. Kim DH, Villeneuve LM, Morris KV, Rossi JJ. Argonaute-1 directs siRNA-mediated transcriptional gene silencing in human cells. Nucleic Acids Res 2006; 34:7597-605; PMID:16936726; http://dx.doi.org/10.1093/nar/gkq1042.
7. Liu Y, Long M, Nan B, Wilson HH. Congruent transcription through a long CAG repeat destabilizes repeats and induces apoptosis. Mol Cell Biol 2010; 30:4845-51; PMID:20477679; http://dx.doi.org/10.1128/MCB.00383-10.
8. Laska KT, O’Koff LN, Samaniego MS, van Rijn CL, McLeod CJ, Scheynius CA, et al. Double-stranded RNA pol IIIa in polyglutamine disease. Hum Mol Genet 2011; 20:377-90; PMID:21327495; http://dx.doi.org/10.1093/hmg/2001625.
9. Libby RC, Hageman KA, Pizzida VV, Liu B, Chen DH, Baccar S, et al. CTG/CTC virus-like (trinucleotide repeat instability) as an epigenetic signature: a novel basis for mental retardation? PLoS Genet 2006; 2:e82; PMID:16988946; http://dx.doi.org/10.1371/journal.pgen.0020082.
10. Duan Y, Liu Y, Huber JL, Ewald TA, Wilson HH. Dnmt1 deficiency promotes CAG repeat expansion in the mouse germline. Hum Mol Genet 2008; 17:1386-97; PMID:18425277; http://dx.doi.org/10.1093/hmg/ddn019.
11. Roda I, Saffi J, Thompson LM, Marth JL. Altered protein acetylation in polyglutamine disease. Genes Brain Behav 2010; 9:257-77; PMID:20474872; http://dx.doi.org/10.1111/j.1601-183X.2010.00213.x.
12. Jung J, Bounin N. CREB-binding protein modulates expression in the R6/2 model of polyglutamine disease: a novel basis for neuronal loss? J Neurosci 2008; 28:10720-7; PMID:19008940; http://dx.doi.org/10.1523/JNEUROSCI.2126-08.2008.
13. Jung J, Bounin N. CREB-binding protein modulates repeat instability in a Drosophila model for polyQ disorders. Science 2007; 315:1857-60; PMID:17332275; http://dx.doi.org/10.1126/science.1155971.
14. Dohler K, Wohland A, Glessner G, Rckermann I, Morit T, Lahus RS. Histone deacetylase complexes promote trinucleotide repeat expansions. PLoS Biol 2012; 10:e1001397; PMID:22638309; http://dx.doi.org/10.1371/journal.pbio.1001397.
15. Nishida K, Hikaido M. Huntingtin acts as a protein degradation factor. Neuroreport 1994; 5:1263-7; PMID:7723883; http://dx.doi.org/10.1093/neurol/5.17.1263.
16. Stack DC, Radelis JR, Smith K, Conner K, Dri Sippou SJ, Vagnolo E, et al. The mouse germline. Hum Mol Genet 2008; 17:1386-97; PMID:18425277; http://dx.doi.org/10.1093/hmg/ddn019.
17. Nishida K, Hikaido M. Huntingtin acts as a protein degradation factor. Neuroreport 1994; 5:1263-7; PMID:7723883; http://dx.doi.org/10.1093/neurol/5.17.1263.
18. Stack DC, Radelis JR, Smith K, Conner K, Dri Sippou SJ, Vagnolo E, et al. The mouse germline. Hum Mol Genet 2008; 17:1386-97; PMID:18425277; http://dx.doi.org/10.1093/hmg/ddn019.
19. Morris KV, Chen JW, Jacobson JS, Lessey DE. Small interfering RNA-induced transcriptional gene silencing in human cells. Science 2004; 305:1289-90; PMID:15035262; http://dx.doi.org/10.1126/science.1101672.
20. Duan Y, Liu Y, Huber JL, Ewald TA, Wilson HH. Dnmt1 deficiency promotes CAG repeat expansion in the mouse germline. Hum Mol Genet 2008; 17:1386-97; PMID:18425277; http://dx.doi.org/10.1093/hmg/ddn019.
21. Roda I, Saffi J, Thompson LM, Marth JL. Altered protein acetylation in polyglutamine disease. Genes Brain Behav 2010; 9:257-77; PMID:20474872; http://dx.doi.org/10.1111/j.1601-183X.2010.00213.x.
22. Jorg J, Bounin N. CREB-binding protein modulates expression in the R6/2 model of polyglutamine disease: a novel basis for neuronal loss? J Neurosci 2008; 28:10720-7; PMID:19008940; http://dx.doi.org/10.1523/JNEUROSCI.2126-08.2008.
27. Pahonk CL, Anderson DJ. The neuroprotective silence factor (NKSF), a coordinate represor of multiple microglial acute-phase genes. J Biol Chem 2001; 276:3047-53; PMID:11265495.

28. Liao Z, Shen Y, Li M, Li S, Guo J, Zhao Z, Lin J, et al. HDAC inhibitors target neuronal pathways and improve spatial learning and memory in the H1-FTD mouse model of Huntingdon's disease. J Neurosci 2012; 32:3219-3230; PMID:22261394; http://dx.doi.org/10.1523/JNEUROSCI.4121-11.2012.

29. Schonherr CL, Anderson DJ. The neuroprotective silence factor (NKSF), a coordinate represor of multiple microglial acute-phase genes. J Biol Chem 2001; 276:3047-53; PMID:11265495.

30. Buckle NJ, Labar PD, Pinuela YY, Libby KT, Scianik SM, Haeberle J, et al. CTCF regulates anti-7 tran- scription through demethylation of a symmetrically methylated alcohol. Neurogenetics 2011; 12:701-8; PMID:21849184; http://dx.doi.org/10.1007/s10048-011-0015-z.

31. Moriyuki M, Tachibana K. Pathways Downstream of hnRNP A2/3. Mol Neurobiol 2012; 46:351-62; PMID:22397724; http://dx.doi.org/10.1007/s12035-011-9139-2.

32. Peron AE, Maller JL, Atassi SH, Falaschi J, Jin L. The role of small H3K9m2 histones in the modulation of F质 protein expression in the R6/2 mouse model of Huntington's disease. J Neurochem 2011; 117:765-76; PMID:21626785; http://dx.doi.org/10.1111/j.1471-4159.2011.07409.x.

33. Sato M, Nomura T, Ikeda Y, Daughters RS, Ranum LP. Bidirectional expression of the SC2 natural antisense transcript at the Huntington's disease natural antisense transcript, in transgenic mouse models of Huntington's disease. Hum Mol Genet 2011; 20:2204-12; PMID:21427130; http://dx.doi.org/10.1093/hmg/ddr108.

34. Giorgini F, Möller B, Bertoni AM, Fan Y, et al. Polyglutamine-expanded ataxin-7 inhibits HDAC6 and HDAC1 and downregulates expression of SCA8 and SCA8-dependent genes in human cells. J Biol Chem 2008; 283:7390-400; PMID:18079112; http://dx.doi.org/10.1073/pnas.0800467105.

35. Badwal S, Pahonk CL, Anderson DJ, Fischbeck KH, Min KT. Aberrant histone acetylation, methylation. Hum Mol Genet 2008; 17:1393-406; PMID:18272831; http://dx.doi.org/10.1093/hmg/ddn067.

36. Zheng Y, Boutros MC, et al. REST: a mamma- nalian orthologue of DREBA1. J Biol Chem 2001; 276:26452-6; PMID:11507998; http://dx.doi.org/10.1074/jbc.M104828200.

37. Fischbeck KH, Min KT. Aberrant histone acetylation, methylation. Hum Mol Genet 2008; 17:1393-406; PMID:18272831; http://dx.doi.org/10.1093/hmg/ddn067.

38. Bett JS, Barennes C, Le Fur L, et al. H3K4, H3K36 and H3K79 trimethylation, histone acetylation, covalent modification in the R6/2 mouse model of Huntington's disease. J Neurochem 2011; 118:24-36; PMID:21839320; http://dx.doi.org/10.1111/j.1471-4159.2011.07620.x.

39. Fischbeck KH, Min KT. Aberrant histone acetylation, methylation. Hum Mol Genet 2008; 17:1393-406; PMID:18272831; http://dx.doi.org/10.1093/hmg/ddn067.

40. Fischbeck KH, Min KT. Aberrant histone acetylation, methylation. Hum Mol Genet 2008; 17:1393-406; PMID:18272831; http://dx.doi.org/10.1093/hmg/ddn067.

41. Fischbeck KH, Min KT. Aberrant histone acetylation, methylation. Hum Mol Genet 2008; 17:1393-406; PMID:18272831; http://dx.doi.org/10.1093/hmg/ddn067.

42. Fischbeck KH, Min KT. Aberrant histone acetylation, methylation. Hum Mol Genet 2008; 17:1393-406; PMID:18272831; http://dx.doi.org/10.1093/hmg/ddn067.

43. Fischbeck KH, Min KT. Aberrant histone acetylation, methylation. Hum Mol Genet 2008; 17:1393-406; PMID:18272831; http://dx.doi.org/10.1093/hmg/ddn067.

44. Fischbeck KH, Min KT. Aberrant histone acetylation, methylation. Hum Mol Genet 2008; 17:1393-406; PMID:18272831; http://dx.doi.org/10.1093/hmg/ddn067.

45. Fischbeck KH, Min KT. Aberrant histone acetylation, methylation. Hum Mol Genet 2008; 17:1393-406; PMID:18272831; http://dx.doi.org/10.1093/hmg/ddn067.

46. Fischbeck KH, Min KT. Aberrant histone acetylation, methylation. Hum Mol Genet 2008; 17:1393-406; PMID:18272831; http://dx.doi.org/10.1093/hmg/ddn067.

47. Fischbeck KH, Min KT. Aberrant histone acetylation, methylation. Hum Mol Genet 2008; 17:1393-406; PMID:18272831; http://dx.doi.org/10.1093/hmg/ddn067.

48. Fischbeck KH, Min KT. Aberrant histone acetylation, methylation. Hum Mol Genet 2008; 17:1393-406; PMID:18272831; http://dx.doi.org/10.1093/hmg/ddn067.

49. Fischbeck KH, Min KT. Aberrant histone acetylation, methylation. Hum Mol Genet 2008; 17:1393-406; PMID:18272831; http://dx.doi.org/10.1093/hmg/ddn067.

50. Fischbeck KH, Min KT. Aberrant histone acetylation, methylation. Hum Mol Genet 2008; 17:1393-406; PMID:18272831; http://dx.doi.org/10.1093/hmg/ddn067.

51. Fischbeck KH, Min KT. Aberrant histone acetylation, methylation. Hum Mol Genet 2008; 17:1393-406; PMID:18272831; http://dx.doi.org/10.1093/hmg/ddn067.

52. Fischbeck KH, Min KT. Aberrant histone acetylation, methylation. Hum Mol Genet 2008; 17:1393-406; PMID:18272831; http://dx.doi.org/10.1093/hmg/ddn067.

53. Fischbeck KH, Min KT. Aberrant histone acetylation, methylation. Hum Mol Genet 2008; 17:1393-406; PMID:18272831; http://dx.doi.org/10.1093/hmg/ddn067.

54. Fischbeck KH, Min KT. Aberrant histone acetylation, methylation. Hum Mol Genet 2008; 17:1393-406; PMID:18272831; http://dx.doi.org/10.1093/hmg/ddn067.

55. Fischbeck KH, Min KT. Aberrant histone acetylation, methylation. Hum Mol Genet 2008; 17:1393-406; PMID:18272831; http://dx.doi.org/10.1093/hmg/ddn067.

56. Fischbeck KH, Min KT. Aberrant histone acetylation, methylation. Hum Mol Genet 2008; 17:1393-406; PMID:18272831; http://dx.doi.org/10.1093/hmg/ddn067.
63. Polka J, Bedke J, Lukaszczyk T, Purdon DM, Steffen JS, Thompson LM, et al. Inhibition of specific HDMCs and histone deacetylases improves histone H4 acetylation in a Drosophila model of Huntington’s disease. Hum Mol Genet 2006; 15:357-70, PMID:16582557; http://dx.doi.org/10.1093/hmg/ddi273.

64. Jung M, Wang J, Xu J, Lu J, Jing H, West T, et al. Nonneuroprotective role of SIRT1 in maximum levels of Huntington’s disease through activation of multiple Sirt1 targets. Nat Mol Med 2012; 18:153-63, PMID:22173915; http://dx.doi.org/10.1038/nm.2538.

65. Bous CL, Bedke J, Larner L, Nuss J, Moffett R, Mahmoud M, et al. Genetic knockout of HDMC7 does not ameliorate disease pathogenesis in the R6/2 mouse model of Huntington’s disease. PLoS ONE 2009; 4:e7847, PMID:19484427; http://dx.doi.org/10.1371/journal.pone.0007847.

66. Mousavi L, Campbell K, Houdard D, Orszag Y, Qin G. Genetic knockout of HDMC7 does not modify disease-related phenotypes in a mouse model of Huntington’s disease. PLoS ONE 2013; 8:e10180, PMID:24231473; http://dx.doi.org/10.1371/journal.pone.0081080.

67. Behroozvanda A, Pagnotto P, Marani M, Penn G. Hicd1 knockout increases robust axonation but does not modify disease phenotype in the R6/1 mouse model of Huntington’s disease. PLoS ONE 2011; 6:e23088, PMID:22027777; http://dx.doi.org/10.1371/journal.pone.0023088.

68. Thomson JA, Itskovitz-Eldor J, Shapiro SS, Waknitz MA, Swiergiel JJ, Marshall VS, et al. Embryonic stem cell lines derived from human blastocysts. Science 1998; 282:1145-7; PMID:9804556; http://dx.doi.org/10.1126/science.282.5391.1145.

69. Thomson JA, Itskovitz-Eldor J, Shapiro SS, Waknitz MA, Swiergiel JJ, Marshall VS, et al. Characterization of Human Huntington’s Disease Cell Model. PLoS ONE 2011; 6:e20158, PMID:21677773; http://dx.doi.org/10.1371/journal.pone.0020158.

70. Jiang M, Wang P, Ji Y, Li M, Zhang XG, Thomson JA, et al. Neural differentiation of human induced pluripotent stem cells: feasibility and with variable potency. Proc Natl Acad Sci USA 2010; 107:4376-81, PMID:20326689; http://dx.doi.org/10.1073/pnas.0912813107.

71. Knobloch O, Hamilton BS, Mattila B. Conditional Generation and Differentiation of Neural Precursor Cells from Human Pluripotent Stem Cells. Stem Cell Res 2012; PMID:22388559; http://dx.doi.org/10.1016/j.stemcr.2012.02.007.

72. Lee KH, Chang HS, Sohn KS. Derivation, propagation, and characterization of neuroprogenitors from pluripotent stem cells (HESG and KKP6). Methods Mol Biol 2012; 873:257-66, PMID:22586999; http://dx.doi.org/10.1007/978-1-61779-796-1_15.

73. Chan AK, Cheng PM, Newman A, Yang J. Reprogramming Huntington monkey skin cells into pluripotent stem cells. Cell Reprogram 2010; 12:509-17, PMID:20390982; http://dx.doi.org/10.1080/10920850903484109.

74. Cunningham C, Carl AG, Lombardo A, Giel I, Manetti C, Cartesius A, et al. The first reported generation of neural induced pluripotent stem cell lines from homogenous and heterogeneous Huntington’s disease patients demonstrates mutation related enhanced lysosomal activity. Neurobiol Dis 2012; 46:41-51, PMID:22169506; http://dx.doi.org/10.1016/j.nbd.2012.11.062.

75. Crippaoui N, Ouzouni M, Boccon-Griffon V, Camussi G. Induced pluripotent stem cells lines from Huntington disease mice undergo neuronal differentiation while showing alterations in the lysosomal pathway. Neurobiol Dis 2011; 44:60-9, PMID:21327900; http://dx.doi.org/10.1016/j.nbd.2011.12.012.

76. Zhang N, An MC, Monsuro D, Fletcher LM. Characterization of Human Huntington’s Disease Cell Model from Induced Pluripotent Stem Cells. PLoS ONE 2012; 7:e31080, PMID:22347433; http://dx.doi.org/10.1371/journal.pone.0031080.

77. Juopperi T, et al. Neuroprotective role of Sirt1 in mammalian, experimental, and clinical studies. Front Cell Neurosci 2010; 4:RRN1193; PMID:21037797; http://dx.doi.org/10.3389/fncel.2010.00193.

78. Alves AP, Turela A, Dasgupta D, Taverna S, Leo D, et al. Marked differences in differentiation propensity among human embryonic stem cell lines derived and maintained lines. Hum Mol Genet 2007; 16:R195-204, PMID:17812850; http://dx.doi.org/10.1093/hmg/ddm245.

79. Caiazzo M, D’Amato MT, D’Oropizio E, Lammert D, Turrini T, Tian L, et al. Direct generation of functional dopaminergic neurons from mouse and human fibroblasts. Nature 2011; 476:224-7, PMID:21725246; http://dx.doi.org/10.1038/nature10284.

80. Yang ZF, Yang N, Verhoeven T, Dorsman JC, Dierschke DB, Yang JZ, et al. Induction of human neuronal cells by defined transcription factors. Nature 2011; 476:228-33, PMID:21617644.

81. Minucci U, Ward J, Nitzkog K, Halpern O, Bijur E, Wengler G, Thomson G, et al. Efficient induction of functional neurons from adult human telencephalon. Cell Cycle 2011; 10:3311-6, PMID:22013948; http://dx.doi.org/10.4161/cc.10.19.17584.

82. Liang Q, Fan LA, Yamada T, Angulo S, Rizzo H, Duso D, et al. Directed conversion of Alzheimer’s disease patient skin fibroblasts into functional neural stem cells. Nature 2011; 461:395-9, PMID:21481627; http://dx.doi.org/10.1038/nature08320.

83. Yoo AS, Sun AX, Li L, Schlegelmilch A, Pericak-Vance M, Li Y, et al. MicroRNA-mediated conversion of human fetal neural progenitors into induced pluripotent stem cells. Stem Cells 2012; 30:935-46; PMID:22528359; http://dx.doi.org/10.1002/stem.205.

84. Anno MT, Dvoretskova E, Lazarevic J, Nihlberg K, Hallgren O, et al. Anno MT, Dvoretskova E, Lazarevic J, Nihlberg K, Hallgren O, et al. Induced Pluripotent Stem Cells from Human Pluripotent Stem Cells. Stem Cells 2012; 30:935-46; PMID:22528359; http://dx.doi.org/10.1002/stem.205.

85. Pan J, Tsai SP, Ohmori Y, Fujita R, Yoshida E, et al. MicroRNA-21mediated conversion of Alzheimer’s disease patient skin fibroblasts into functional neural stem cells. Cell Stem Cell 2012; 10:153-63, PMID:22405424; http://dx.doi.org/10.1016/j.stem.2012.02.006.

86. Pan J, Tsai SP, Ohmori Y, Fujita R, Yoshida E, et al. MicroRNA-21mediated conversion of Alzheimer’s disease patient skin fibroblasts into functional neural stem cells. Cell Stem Cell 2012; 10:153-63, PMID:22405424; http://dx.doi.org/10.1016/j.stem.2012.02.006.

87. Yang ZF, Yang N, Verhoeven T, Dorsman JC, Dierschke DB, Yang JZ, et al. Induction of human neuronal cells by defined transcription factors. Nature 2011; 476:228-33, PMID:21617644.

88. Minucci U, Ward J, Nitzkog K, Halpern O, Bijur E, Wengler G, Thomson G, et al. Efficient induction of functional neurons from adult human telencephalon. Cell Cycle 2011; 10:3311-6, PMID:22013948; http://dx.doi.org/10.4161/cc.10.19.17584.

89. Liang Q, Fan LA, Yamada T, Angulo S, Rizzo H, Duso D, et al. Directed conversion of Alzheimer’s disease patient skin fibroblasts into functional neural stem cells. Nature 2011; 461:395-9, PMID:21481627; http://dx.doi.org/10.1038/nature08320.